1. Search Result
Search Result
Results for "

RNA virus replication

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Natural
Products

5

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10241
    Simeprevir
    Maximum Cited Publications
    40 Publications Verification

    TMC435; TMC435350

    HCV HCV Protease SARS-CoV DNA/RNA Synthesis Infection
    Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
    Simeprevir
  • HY-B1537

    2',3',5'-Tri-O-acetyl-6-azauridine

    Virus Protease Influenza Virus Infection Inflammation/Immunology
    Azaribine (2',3',5'-Tri-O-acetyl-6-azauridine) is a potent orotidine monophosphate decarboxylase (OMPD) inhibitor. Azaribine is an antiviral inhibitor of several RNA viruses and inhibits viral genome replication and gene transcription. Azaribine shows broad-spectrum antiviral activity (EC50=3.80 nM-1.73 μM against influenza A and B viruses; EC50=1.62 μM against ZIKV Paraiba). Azaribine, a triacetate salt of Azauridine, has the potential for psoriasis research .
    Azaribine
  • HY-125371
    2'-C-Methyladenosine
    2 Publications Verification

    HCV Infection Inflammation/Immunology
    2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication. 2'-C-Methyladenosine inhibits HCV replicon and NS5B-catalyzed RNA synthesis with IC50 values of 0.3μM and 1.9 μM, respectively. 2'-C-Methyladenosine also potently inhibits LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis .
    2'-C-Methyladenosine
  • HY-15005B

    Drug Metabolite Others
    Sofosbuvir impurity C is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir impurity C
  • HY-148167

    DNA/RNA Synthesis Virus Protease Infection
    2'-Deoxy-2'-fluoro-l-uridine is an L-nucleoside compound. 2'-Deoxy-2'-fluoro-l-uridine is a potent, selective viral RNA polymerase inhibitor, thereby inhibiting RNA virus replication .
    2'-Deoxy-2'-fluoro-l-uridine
  • HY-109072

    SARS-CoV Infection
    Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of SARS-CoV-2 .
    Riamilovir
  • HY-10241A

    TMC435 sodium; TMC435350 sodium

    HCV HCV Protease SARS-CoV DNA/RNA Synthesis Infection
    Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
    Simeprevir sodium
  • HY-10241S

    TMC435-13C,d3; TMC435350-13C,d3

    Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis Infection
    Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].
    Simeprevir-13C,d3
  • HY-19111

    TIBO-R 82150

    HIV Reverse Transcriptase Infection
    R-82150 (TIBO-R 82150) is an HIV-1 reverse transcriptase inhibitor that blocks the reverse transcription of viral RNA by binding to the non-substrate binding site of reverse transcriptase, thereby inhibiting viral replication. R-82150 does not inhibit the replication of HIV-2, other RNA viruses, and DNA viruses .
    R-82150
  • HY-111003

    NZ-4

    HBV Infection
    Isothiafludine is an orally active non-nucleosidic anti-HBV compound. Isothiafludine inhibits hepatitis B virus replication by blocking pregenomic RNA encapsidation .
    Isothiafludine
  • HY-I0719

    Drug Metabolite Others
    Sofosbuvir impurity B is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir impurity B
  • HY-I0723

    Drug Metabolite Others
    Sofosbuvir impurity D is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir impurity D
  • HY-I0727

    Drug Metabolite Others
    Sofosbuvir impurity E is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir impurity E
  • HY-163532

    Sirtuin Infection
    FLS-359 is a selective, orally active allosteric modulator for sirtuin 2, with the IC50 of 3 μM. FLS-359 exhibits antiviral activity against RNA and DNA virus, through inhibition of DNA/RNA replication .
    FLS-359
  • HY-15005C

    HCV Infection
    Sofosbuvir impurity A, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity A
  • HY-I1196

    HCV Infection
    Sofosbuvir impurity L, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity L
  • HY-I0512

    HCV Infection
    Sofosbuvir impurity I, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity I
  • HY-I0735

    HCV Infection
    Sofosbuvir impurity M, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity M
  • HY-I0513

    HCV Others
    Sofosbuvir impurity N, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity N
  • HY-I0406

    HCV Infection
    Sofosbuvir impurity F, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity F
  • HY-I0408

    HCV Others
    Sofosbuvir impurity G, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity G
  • HY-I0515

    HCV Infection
    Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity K
  • HY-I0938

    HCV Infection
    Sofosbuvir impurity H, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity H
  • HY-I0975

    HCV Infection
    Sofosbuvir impurity J, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
    Sofosbuvir impurity J
  • HY-W128400

    DNA/RNA Synthesis HCV Infection
    3′-Deoxy-3′-fluoroguanosine exhibits antiviral activity against tick-borne encephalitis virus (TBEV), through interaction with NS5B RdRp of HCV, resulting in suppression of viral RNA synthesis by disruption of further extension of the replicating viral RNA .
    3′-Deoxy-3′-fluoroguanosine
  • HY-15005S1

    PSI-7977-d6; GS-7977-d6

    HCV Infection
    Sofosbuvir-d6 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir-d6
  • HY-15005S

    PSI-7977-13C,d3; GS-7977-13C,d3

    Isotope-Labeled Compounds HCV Infection
    Sofosbuvir- 13C,d3 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    Sofosbuvir-13C,d3
  • HY-15005A

    HCV Infection
    PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
    PSI-7976
  • HY-149050

    Influenza Virus SARS-CoV Infection
    Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC90 values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against SARS-CoV-2 infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .
    Viral polymerase-IN-1 hydrochloride
  • HY-109025A
    Baloxavir
    25+ Cited Publications

    Baloxavir acid; S-033447

    Influenza Virus Infection Cancer
    Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .
    Baloxavir
  • HY-139158

    HIV Infection
    Ainuovirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Ainuovirine inhibits HIV replication by non-competitively binding to HIV reverse transcriptase and blocking the reverse transcription process of viral RNA. Ainuovirine can be used for human immunodeficiency virus (HIV) type 1 infection .
    Ainuovirine
  • HY-146246
    EIDD-2749
    1 Publications Verification

    4'-FlU; 4'-Fluorouridine

    RSV SARS-CoV HCV Infection
    EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses .
    EIDD-2749
  • HY-147885

    HCV Infection
    HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC50 value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication .
    HCV-IN-41
  • HY-109025AS

    Baloxavir acid-d5; S-033447-d5

    Isotope-Labeled Compounds Influenza Virus Infection
    Baloxavir-d5 is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].
    Baloxavir-d5
  • HY-N8188

    HCV HCV Protease Infection
    Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35?μM) .
    Dehydrojuncusol
  • HY-109025AR

    Influenza Virus Infection
    Baloxavir (Standard) is the analytical standard of Baloxavir. This product is intended for research and analytical applications. Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity .
    Baloxavir (Standard)
  • HY-131603

    3TCTP

    Reverse Transcriptase HCV HBV SARS-CoV Infection
    Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the Reverse Transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
    Lamivudine triphosphate
  • HY-138577

    DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Others
    2'-F-Bz-dC Phosphoramidite can be used in the synthesis of oligoribonucleotide (such as DNA and RNA). 2'-F-Bz-dC Phosphoramidite also used for synthesis antiviral agent to inhibit the replication of virus. 2'-F-Bz-dC Phosphoramidite contains a phosphorothioate backbone, to synthesise antisense oligonucleotide analogs to induce apoptosis in cancer cells .
    2'-F-Bz-dC Phosphoramidite
  • HY-153810

    JNJ-1802

    Virus Protease Flavivirus Dengue virus Infection
    Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    Mosnodenvir
  • HY-15256A

    BI 201335 sodium

    HCV Protease Infection
    Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .
    Faldaprevir sodium
  • HY-15256

    BI 201335

    HCV Protease Infection
    Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .
    Faldaprevir
  • HY-136797

    Others Infection
    BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
    BP13944
  • HY-W751835
    Baloxavir-d4
    25+ Cited Publications

    Baloxavir acid-d4; S-033447-d4

    Isotope-Labeled Compounds Others Cancer
    Baloxavir-d4 (Baloxavir acid-d4; S-033447-d4) is the deuterium-labeled Baloxavir (HY-109025A). Baloxavir-d4 (Baloxavir-d4 acid), derived from the proagent Baloxavir-d4 marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir-d4 inhibits viral RNA transcription and replication and has potently antiviral activity .
    Baloxavir-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: